Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Just For You A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBHWritten by Nathan Reiff. Article Published: 2/12/2026. 
Key Takeaways - AstraZeneca, Edwards Lifesciences, and Zimmer Biomet all reported earnings on the same day, but with vastly different results.
- Of these, AstraZeneca's impressive oncology medicine sales growth stands out, having driven significant top-line growth.
- Edwards and Zimmer both saw notable successes in the latest quarter, but also face sizable challenges.
More than just a financial check-up, earnings for companies in the healthcare sector offer a key window for investors into a firm's pipeline and development progress. Even well-established, stable firms in the healthcare space can surprise with growth when a new blockbuster drug or medical device reaches the market, and earnings periods give management a chance to provide context and commentary beyond what investors see in FDA approval notices. When multiple healthcare companies report on the same day, investors can face a deluge of information as they sort through the most important developments and plan trades. On Feb. 10, 2026, three major names in the sector—AstraZeneca (NASDAQ: AZN), Edwards Lifesciences (NYSE: EW), and Zimmer Biomet (NYSE: ZBH)—each reported full-year and Q4 2025 results. Below are highlights and takeaways for investors looking to adjust or confirm their plans based on these updates. AstraZeneca Firms Up Cancer Business in a Strong Overall Quarterly Performance Wall Street Journal best-selling author James Altucher has uncovered a way to get a pre-IPO stake BEFORE Starlink goes public.
All it takes is just a few minutes of time and as little as $100 to get started. Plus, you can take action right inside your regular brokerage account. Click here now to see how to take action. U.K.-based pharma giant AstraZeneca closed out 2025 by further cementing its position in oncology, with cancer medicines accounting for roughly 44% of product sales in the fourth quarter. Sales of therapies such as Imfinzi and Enhertu rose as much as 48% year-over-year (YOY), helping drive total revenue up 8.6% to $58.7 billion for the year. Net income rose alongside revenue, climbing to $10.2 billion from $7.0 billion in the prior-year quarter, and the company's board declared a second interim dividend that was 7 cents higher than last year's. Investors will also be watching AstraZeneca's development pipeline: management said about 20 Phase 3 readouts are expected in 2026, and the firm expects increases in both total revenue and core earnings per share (EPS) for the full year. Following the strong earnings announcement, AZN shares climbed nearly 3% in after-hours trading. While 10 of 11 analysts rate AZN a Buy or equivalent, the consensus price target of $95.75 implies roughly a 51% downside from then-current levels, raising valuation questions among some on Wall Street. TAVR Momentum Fuels Edwards Sales Growth, Though Investors Should Note Margin and EPS Limitations Edwards makes replacement heart valves, associated surgical devices, and monitoring systems. Its Q4 2025 results were largely positive, with sales up 13.3% YOY driven by strong transcatheter aortic valve replacement (TAVR) momentum and the latest SAPIEN valve iteration. However, adjusted EPS missed analyst expectations, and gross profit margin fell by 0.8 percentage points year-over-year. Despite the mixed quarter, Edwards remains confident it can meet its 2026 outlook, which calls for sales growth of 8%–10% YOY and EPS of $2.90–$3.05. EW shares rose about 4% in after-hours trading, pushing above $80. Roughly two-thirds of analysts rate EW a Buy, and the consensus price target of $96.77 implies approximately 25% upside. Orthopedic Demand Remains High, but Zimmer Faces Some Headwinds Zimmer Biomet, a maker of joint replacement systems and implants, saw its shares rise more than 3% after reporting EPS of $2.42, which beat consensus by $0.04, and revenue of $2.2 billion, up nearly 11% YOY and slightly ahead of expectations. Strong demand for Zimmer's orthopedic products helped drive both top- and bottom-line growth. Zimmer is shifting to focus more on U.S. sales, where roughly 60% of its business is concentrated. Rising utilization among insured patients should support near-term demand for the company's products. That said, tariffs remain a potential headwind and could pressure EPS and revenue in 2026. Management provided conservative guidance in the earnings report, forecasting adjusted EPS of $8.30–$8.45 and free cash flow growth of 8%–10%. Analysts were divided ahead of the release, and Zimmer carried an overall Hold rating, despite roughly 15% projected upside by the consensus forecast (source).
| 
